Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy

Woraphot Tantisiriwat, Pablo Tebas, David B. Clifford, William G. Powderly, Carl J. Fichtenbaum

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Abstract

Recent reports suggest that human immunodeficiency virus (HIV)- associated progressive multifocal leukoencephalopathy (PML) may improve with highly active antiretroviral therapy (HAART). We observed three patients who developed PML while receiving HAART. All patients received HAART for 4-11 months and had low plasma levels of HIV-1 RNA before the onset of symptoms of PML. Antiretroviral therapy was changed in two patients, and their plasma HIV-1 RNA levels declined significantly. Despite this virologic response, PML did not improve in these patients. The third patient's HIV-1 RNA level became undetectable while he was receiving HAAT, and his symptoms of PML improved after the addition of interferon α. Our observations suggest that PML can develop in patients who have shown clinical response to HAART. Furthermore, PML may not improve despite an adequate virologic response to HAART. Definitive therapy is still needed for PML.

Original languageEnglish
Pages (from-to)1152-1154
Number of pages3
JournalClinical Infectious Diseases
Volume28
Issue number5
DOIs
StatePublished - 1999

Fingerprint

Dive into the research topics of 'Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy'. Together they form a unique fingerprint.

Cite this